These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 9146820)

  • 1. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early experience with Suboxone maintenance therapy in Hungary.
    Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
    Negus SS
    J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
    Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
    Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
    Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
    Foltin RW; Fischman MW
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine in the treatment of opiate dependence.
    Wesson DR; Smith DE
    J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.